Talmapimod
Alternative Names: SCIO-469Latest Information Update: 05 Nov 2023
At a glance
- Originator Scios
- Class Analgesics; Anti-inflammatories; Antirheumatics; Indoles; Skin disorder therapies
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Skin disorders
- Discontinued Dental pain; Multiple myeloma; Myelodysplastic syndromes; Rheumatoid arthritis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Skin-disorders in USA (Topical)
- 29 Oct 2008 Final efficacy, adverse events & pharmacokinetics data from the phase II SPRiNG trial in Rheumatoid arthritis presented at the 72nd Annual Scientific Meeting of the American College of Rheumatology and the 43rd Annual Meeting of the Association of Rheumatology Health Professionals (ACR/ARHP-2008)
- 29 Apr 2005 Phase-I/II clinical trials in Myelodysplastic syndromes in USA (PO)